Effects of statins beyond lipid lowering: Potential for clinical benefits

被引:109
作者
Almuti, K
Rimawi, R
Spevack, D
Ostfeld, RJ
机构
[1] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, Div Cardiol, Bronx, NY 10467 USA
[3] Lutheran Med Univ, Dept Med, Brooklyn, NY USA
关键词
statin; lipid lowering; HMG-CoA;
D O I
10.1016/j.ijcard.2005.05.056
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The role of statin drugs in the reduction of serum lipids has been well documented. More recently, evidence suggesting that statins may positively impact many organ systems and disease states independent of lipid reduction has emerged. The term "pleiotropic effects" has been used to refer to these properties. We reviewed the evidence exploring Such potential effects. Methods: A search of the MEDLINE database was conducted for articles published between 1985 to 2005 on the pleiotropic and the lipid-lowering independent effects of statin drugs. The search terms "statin", "HMG-CoA reductase inhibitor", "pleiotropic effects", and "inflammation" were used. English language articles were selected for inclusion along with selected cross-references. Results: Numerous animal and clinical studies support the presence of a spectrum of beneficial effects for statins that are independent of their lipid-lowering properties. These effects are mediated by a variety of mechanisms and they suggest that the therapeutic role of statins may expand. Conclusion: Statins have shown great promise beyond their lipid-lowering effects. Ongoing and future Studies will help to further clarify the potential clinical impact of these "pleiotropic effects". (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 107 条
  • [1] ADAMO P, 1989, CAN J CARDIOL, V5, P395
  • [2] Agarwal B, 1999, CLIN CANCER RES, V5, P2223
  • [3] Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
    Albert, MA
    Danielson, E
    Rifai, N
    Ridker, PM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01): : 64 - 70
  • [4] Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure
    Anker, SD
    Volterrani, M
    Egerer, KR
    Felton, CV
    Kox, WJ
    Poole-Wilson, PA
    Coats, AJS
    [J]. QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1998, 91 (03): : 199 - 203
  • [5] [Anonymous], Drugs
  • [6] Attallah N, 2004, CLIN NEPHROL, V62, P273
  • [7] Use of statins and fracture - Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials
    Bauer, DC
    Mundy, GR
    Jamal, SA
    Black, DM
    Cauley, JA
    Ensrud, KE
    van der Klift, M
    Pols, HAP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (02) : 146 - 152
  • [8] The role of oxidized lipoproteins in atherogenesis
    Berliner, JA
    Heinecke, JW
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 20 (05) : 707 - 727
  • [9] MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN STIMULATES MONOCYTE ENDOTHELIAL INTERACTIONS
    BERLINER, JA
    TERRITO, MC
    SEVANIAN, A
    RAMIN, S
    KIM, JA
    BAMSHAD, B
    ESTERSON, M
    FOGELMAN, AM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) : 1260 - 1266
  • [10] HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
    Bourcier, T
    Libby, P
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) : 556 - 562